[A17-47] Osimertinib (lung cancer) - Addendum to Commission A17-20
Last updated 19.10.2017
Project no.:
A17-47
Commission:
Commission awarded on 12.09.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Advanced NSCLC (lung cancer) with T790M mutation after pretreatment with EGFR-TKI
Result of dossier assessment:
Unchanged hint of non-quantifiable, at least considerable added benefit versus cisplatin + pemetrexed
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-20 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.